A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.

Trial Profile

A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Abiraterone acetate (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 03 May 2018 Planned End Date changed from 9 Apr 2018 to 9 Apr 2021.
    • 03 May 2018 Planned primary completion date changed from 9 Apr 2018 to 9 Apr 2021.
    • 16 Feb 2018 This trial has been completed in Spain, according to European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top